ESM table 1: Drug effects for most commonly prescribed treatment(s) derived from linear mixed model

Drug combination	Estimate (95% CI)	N (total number of measures)
Untreated	REF	33,243 (27.2%)
MONOTHERAPY:		
Metformin:		
<1g	-0.8 (-1.3, -0.4)	1961(1.6%)
≥1g - <2g	-2.8 (-3.0, -2.5)	21317(17.5%)
≥2g	-4.2 (-4.6, -3.9)	10288(8.4%)
SU	-3.4 (-3.7, -3.2)	15781(12.9%)
TZD	-7.4 (-8.3, -6.5)	695(0.6%)
DUAL THERAPY:		
Metformin + SU:		
<1g	-4.5 (-5.2, -3.8)	781(0.6%)
≥1g - <2g	-6.7 (-7.0, -6.3)	8729(7.2%)
≥2g	-9.2 (-9.5, -8.8)	11344(9.3%)
Metformin + TZD:		
≥1g - <2g	-8.2 (-9.0, -7.5)	1190(1.0%)
≥2g	-8.9 (-9.5, -8.4)	2505(2.1%)
SU + TZD	-9.9 (-10.5, -9.3)	2045(1.7%)
≥2g Metformin + DPP4	-7.0 (-7.8, -6.2)	1099(0.9%)
TRIPLE THERAPY:		
Metformin + SU + TZD:		
≥1g - <2g	-13.7 (-14.4, -12.9)	935(0.8%)
≥2g	-16.5 (-17.1, -16.0)	3063(2.5%)
Metformin + SU + DPP4:		
≥1g - <2g	-11.6 (-12.6, -10.7)	593(0.5%)
≥2g	-14.3 (-14.9, -13.7)	2155(1.8%)
≥2g *Metformin + SU + GLP1:*	-17.3 (-18.3, -16.3)	699(0.6%)

SU: Sulphonylureas; TZD: Thiazolidinediones; DPP4: Dipeptidyl Peptidase-4 Inhibitors. GLP1: glucagon-like peptide agonists. The coefficient presented in the table is the effect of the drug(s) on HbA$_{1c}$ characterised in mmol/mol units, with untreated measures as the reference group.

ESM Fig. 1: Study population derivation